Moderna has begun distributing their three-part vaccine to children ages 6 months to 12 years old, called the KidCOVE study. They are currently in phase 2, distributing the vaccine to children 6 months to 12 years old and younger, stated in a report published on Moderna’s website.
Stéphane Bancel, Chief Executive Officer of Moderna, stated they will begin testing the vaccine on healthy children in the United States and in Canada.
During Phase 2, Moderna will be monitoring the safety and effectiveness, along with other protocols in children who have already received the vaccine. After the first dose, children will be given the second dose 28 days later and will be monitored during a 12-month span. In Phase 3, the vaccine will be given to ages 18 years and older. For more information regarding the KidCOVE study, you can visit the Moderna website here: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-0.
For general information on Moderna’s vaccine, you can visit their home page at https://www.modernatx.com.